{"transactions":[{"id":4634360,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":5312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests in 48 equal monthly installments following January 16, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":25235,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":5312},"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634359,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":15650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested."}],"balance_after":51150,"derivative":{"exercise_price":19.19,"expiration_date":"2032-04-17","underlying":"Common Stock","underlying_shares":15650},"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634358,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":28438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":49562,"derivative":{"exercise_price":23.42,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":28438},"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634357,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":9229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":29291,"derivative":{"exercise_price":38.98,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":9229},"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634356,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"sale","planned":true,"acquired":false,"shares":46034,"price":141.78,"value":6526700.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.16 to $143.45. Upon request by the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":59003,"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634355,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"sale","planned":true,"acquired":false,"shares":12595,"price":141.77,"value":1785593.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.21 to $143.31. Upon request by the staff of the U.S. Securities and Exchange Commission (the \"SEC\"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":105037,"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634354,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":5312,"price":12.17,"value":64647.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":117632,"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634353,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":15650,"price":19.19,"value":300323.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":112320,"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634352,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":28438,"price":23.42,"value":666017.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":96670,"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":4634351,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:10:06.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":9229,"price":38.98,"value":359746.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":68232,"source":{"system":"sec-edgar","filing":"0001104659-26-113279","document":"tm2626857-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926113279/tm2626857-1_4seq1.xml","form_type":"4"}},{"id":803795,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-21T20:58:35.000Z","date":"2026-04-20","kind":"sale","planned":false,"acquired":false,"shares":1750,"price":105.47,"value":184572.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":59003,"source":{"system":"sec-edgar","filing":"0001104659-26-046110","document":"tm2612380-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926046110/tm2612380-2_4seq1.xml","form_type":"4"}},{"id":826512,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-27T23:33:56.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":false,"shares":5265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":13282,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":5265},"source":{"system":"sec-edgar","filing":"0001104659-26-036317","document":"tm2610129-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926036317/tm2610129-1_4seq1.xml","form_type":"4"}},{"id":826511,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-27T23:33:56.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":false,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":31300,"derivative":{"exercise_price":19.19,"expiration_date":"2032-04-18","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001104659-26-036317","document":"tm2610129-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926036317/tm2610129-1_4seq1.xml","form_type":"4"}},{"id":826510,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-27T23:33:56.000Z","date":"2026-03-26","kind":"sale","planned":false,"acquired":false,"shares":24765,"price":104.24,"value":2581503.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $104.00 to $104.465. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":60753,"source":{"system":"sec-edgar","filing":"0001104659-26-036317","document":"tm2610129-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926036317/tm2610129-1_4seq1.xml","form_type":"4"}},{"id":826509,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-27T23:33:56.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":true,"shares":5265,"price":12.17,"value":64075.05,"ownership":{"direct":true},"balance_after":85518,"source":{"system":"sec-edgar","filing":"0001104659-26-036317","document":"tm2610129-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926036317/tm2610129-1_4seq1.xml","form_type":"4"}},{"id":826508,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-27T23:33:56.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":true,"shares":19500,"price":19.19,"value":374205.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 433 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2026."}],"balance_after":80253,"source":{"system":"sec-edgar","filing":"0001104659-26-036317","document":"tm2610129-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926036317/tm2610129-1_4seq1.xml","form_type":"4"}},{"id":930140,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:20:42.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":18547,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001104659-26-007128","document":"tm264253-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926007128/tm264253-2_4seq1.xml","form_type":"4"}},{"id":930139,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:20:42.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":50800,"derivative":{"exercise_price":19.19,"expiration_date":"2032-04-18","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-26-007128","document":"tm264253-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926007128/tm264253-2_4seq1.xml","form_type":"4"}},{"id":930138,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:20:42.000Z","date":"2026-01-27","kind":"sale","planned":false,"acquired":false,"shares":18203,"price":83.14,"value":1513397.42,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.80 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":60320,"source":{"system":"sec-edgar","filing":"0001104659-26-007128","document":"tm264253-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926007128/tm264253-2_4seq1.xml","form_type":"4"}},{"id":930137,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:20:42.000Z","date":"2026-01-27","kind":"sale","planned":false,"acquired":false,"shares":28000,"price":83.13,"value":2327640.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.77 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":78523,"source":{"system":"sec-edgar","filing":"0001104659-26-007128","document":"tm264253-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926007128/tm264253-2_4seq1.xml","form_type":"4"}},{"id":930136,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:20:42.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":true,"shares":12000,"price":12.17,"value":146040.0,"ownership":{"direct":true},"balance_after":106523,"source":{"system":"sec-edgar","filing":"0001104659-26-007128","document":"tm264253-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926007128/tm264253-2_4seq1.xml","form_type":"4"}},{"id":930135,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:20:42.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":true,"shares":16000,"price":19.19,"value":307040.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 446 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2025."}],"balance_after":94523,"source":{"system":"sec-edgar","filing":"0001104659-26-007128","document":"tm264253-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926007128/tm264253-2_4seq1.xml","form_type":"4"}},{"id":934385,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-21T22:15:14.000Z","date":"2026-01-20","kind":"sale","planned":false,"acquired":false,"shares":8588,"price":82.48,"value":708338.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":78077,"source":{"system":"sec-edgar","filing":"0001104659-26-005440","document":"tm263774-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926005440/tm263774-1_4seq1.xml","form_type":"4"}},{"id":947174,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T00:37:03.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":32000,"derivative":{"exercise_price":87.18,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001104659-26-001472","document":"tm262304-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926001472/tm262304-2_4seq1.xml","form_type":"4"}},{"id":947173,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-07T00:37:03.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":25600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":86665,"source":{"system":"sec-edgar","filing":"0001104659-26-001472","document":"tm262304-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465926001472/tm262304-2_4seq1.xml","form_type":"4"}},{"id":1167175,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-04-23T20:30:15.000Z","date":"2025-04-22","kind":"sale","planned":false,"acquired":false,"shares":1756,"price":46,"value":80776.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":61065,"source":{"system":"sec-edgar","filing":"0001104659-25-038036","document":"tm2513020-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465925038036/tm2513020-1_4seq1.xml","form_type":"4"}},{"id":1205911,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-14T22:20:46.000Z","date":"2025-03-12","kind":"exercise","planned":false,"acquired":false,"shares":9700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":66800,"derivative":{"exercise_price":19.19,"expiration_date":"2032-04-18","underlying":"Common Stock","underlying_shares":9700},"source":{"system":"sec-edgar","filing":"0001104659-25-024062","document":"tm259281-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465925024062/tm259281-1_4seq1.xml","form_type":"4"}},{"id":1205910,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-14T22:20:46.000Z","date":"2025-03-12","kind":"exercise","planned":false,"acquired":false,"shares":15203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":30547,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":15203},"source":{"system":"sec-edgar","filing":"0001104659-25-024062","document":"tm259281-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465925024062/tm259281-1_4seq1.xml","form_type":"4"}},{"id":1205909,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-14T22:20:46.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":24903,"price":58.73,"value":1462553.19,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.12 to $59.235. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":62821,"source":{"system":"sec-edgar","filing":"0001104659-25-024062","document":"tm259281-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465925024062/tm259281-1_4seq1.xml","form_type":"4"}},{"id":1205908,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-14T22:20:46.000Z","date":"2025-03-12","kind":"exercise","planned":false,"acquired":true,"shares":9700,"price":19.19,"value":186143.0,"ownership":{"direct":true},"balance_after":87724,"source":{"system":"sec-edgar","filing":"0001104659-25-024062","document":"tm259281-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465925024062/tm259281-1_4seq1.xml","form_type":"4"}},{"id":1205907,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-14T22:20:46.000Z","date":"2025-03-12","kind":"exercise","planned":false,"acquired":true,"shares":15203,"price":12.17,"value":185020.51,"ownership":{"direct":true},"balance_after":78024,"source":{"system":"sec-edgar","filing":"0001104659-25-024062","document":"tm259281-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465925024062/tm259281-1_4seq1.xml","form_type":"4"}},{"id":1300332,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-17T22:45:25.000Z","date":"2025-01-16","kind":"sale","planned":false,"acquired":false,"shares":2601,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":62821,"source":{"system":"sec-edgar","filing":"0001104659-25-004569","document":"tm253633-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465925004569/tm253633-1_4seq1.xml","form_type":"4"}},{"id":1300331,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-17T22:45:25.000Z","date":"2025-01-16","kind":"sale","planned":false,"acquired":false,"shares":1317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":65422,"source":{"system":"sec-edgar","filing":"0001104659-25-004569","document":"tm253633-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465925004569/tm253633-1_4seq1.xml","form_type":"4"}},{"id":1311131,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T23:05:16.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":38520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":38520,"derivative":{"exercise_price":38.98,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":38520},"source":{"system":"sec-edgar","filing":"0001104659-25-001426","document":"tm252003-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465925001426/tm252003-1_4seq1.xml","form_type":"4"}},{"id":1311130,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-06T23:05:16.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":31779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":66739,"source":{"system":"sec-edgar","filing":"0001104659-25-001426","document":"tm252003-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465925001426/tm252003-1_4seq1.xml","form_type":"4"}},{"id":1407846,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-13T20:35:19.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":45750,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-24-099838","document":"tm2423879-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924099838/tm2423879-2_4seq1.xml","form_type":"4"}},{"id":1407845,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-13T20:35:19.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":76500,"derivative":{"exercise_price":19.19,"expiration_date":"2032-04-18","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-24-099838","document":"tm2423879-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924099838/tm2423879-2_4seq1.xml","form_type":"4"}},{"id":1407844,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-13T20:35:19.000Z","date":"2024-09-11","kind":"sale","planned":false,"acquired":false,"shares":12000,"price":44.47,"value":533640.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.43 to $44.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":34960,"source":{"system":"sec-edgar","filing":"0001104659-24-099838","document":"tm2423879-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924099838/tm2423879-2_4seq1.xml","form_type":"4"}},{"id":1407843,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-13T20:35:19.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":true,"shares":6000,"price":12.17,"value":73020.0,"ownership":{"direct":true},"balance_after":46960,"source":{"system":"sec-edgar","filing":"0001104659-24-099838","document":"tm2423879-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924099838/tm2423879-2_4seq1.xml","form_type":"4"}},{"id":1407842,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-13T20:35:19.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":true,"shares":6000,"price":19.19,"value":115140.0,"ownership":{"direct":true},"balance_after":40960,"source":{"system":"sec-edgar","filing":"0001104659-24-099838","document":"tm2423879-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924099838/tm2423879-2_4seq1.xml","form_type":"4"}},{"id":1407841,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-13T20:35:19.000Z","date":"2024-09-11","kind":"sale","planned":false,"acquired":false,"shares":2203,"price":44.59,"value":98231.77,"ownership":{"direct":true},"balance_after":34960,"source":{"system":"sec-edgar","filing":"0001104659-24-099838","document":"tm2423879-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924099838/tm2423879-2_4seq1.xml","form_type":"4"}},{"id":1538523,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-04-20T00:05:12.000Z","date":"2024-04-18","kind":"sale","planned":false,"acquired":false,"shares":1234,"price":25.11,"value":30985.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":37163,"source":{"system":"sec-edgar","filing":"0001104659-24-049567","document":"tm2412317-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924049567/tm2412317-1_4seq1.xml","form_type":"4"}},{"id":1607615,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T01:45:27.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant."}],"balance_after":51750,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001104659-24-030156","document":"tm247765-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924030156/tm247765-1_4seq1.xml","form_type":"4"}},{"id":1607614,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-02T01:45:27.000Z","date":"2024-03-01","kind":"sale","planned":false,"acquired":false,"shares":2248,"price":32.33,"value":72677.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.39. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":38397,"source":{"system":"sec-edgar","filing":"0001104659-24-030156","document":"tm247765-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924030156/tm247765-1_4seq1.xml","form_type":"4"}},{"id":1607613,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-02T01:45:27.000Z","date":"2024-03-01","kind":"sale","planned":false,"acquired":false,"shares":12000,"price":32.22,"value":386640.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.17 to $32.31. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":40645,"source":{"system":"sec-edgar","filing":"0001104659-24-030156","document":"tm247765-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924030156/tm247765-1_4seq1.xml","form_type":"4"}},{"id":1607612,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-02T01:45:27.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":true,"shares":12000,"price":12.17,"value":146040.0,"ownership":{"direct":true},"balance_after":52645,"source":{"system":"sec-edgar","filing":"0001104659-24-030156","document":"tm247765-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924030156/tm247765-1_4seq1.xml","form_type":"4"}},{"id":1607611,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-02T01:45:27.000Z","date":"2024-02-29","kind":"sale","planned":false,"acquired":false,"shares":2089,"price":31,"value":64759.0,"ownership":{"direct":true},"balance_after":40645,"source":{"system":"sec-edgar","filing":"0001104659-24-030156","document":"tm247765-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924030156/tm247765-1_4seq1.xml","form_type":"4"}},{"id":1607610,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-02T01:45:27.000Z","date":"2024-02-29","kind":"sale","planned":false,"acquired":false,"shares":7850,"price":30.61,"value":240288.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.57 to $30.76. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":42734,"source":{"system":"sec-edgar","filing":"0001104659-24-030156","document":"tm247765-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924030156/tm247765-1_4seq1.xml","form_type":"4"}},{"id":1676659,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-19T01:00:12.000Z","date":"2024-01-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":1452,"price":24.63,"value":35762.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 3,541 restricted stock units on January 15, 2024."}],"balance_after":50584,"source":{"system":"sec-edgar","filing":"0001104659-24-004899","document":"tm243616-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924004899/tm243616-1_4seq1.xml","form_type":"4"}},{"id":1688389,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T01:07:32.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":78000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":78000,"derivative":{"exercise_price":23.42,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":78000},"source":{"system":"sec-edgar","filing":"0001104659-24-001489","document":"tm241954-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924001489/tm241954-1_4seq1.xml","form_type":"4"}},{"id":1688388,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-05T01:07:32.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in three equal annual installments on January 15, 2025, 2026 and 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":52036,"source":{"system":"sec-edgar","filing":"0001104659-24-001489","document":"tm241954-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465924001489/tm241954-1_4seq1.xml","form_type":"4"}},{"id":1870384,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-02T23:48:09.000Z","date":"2023-05-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":4150,"price":26.07,"value":108190.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the \"Lock-up Date\") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date."}],"balance_after":31036,"source":{"system":"sec-edgar","filing":"0001104659-23-067689","document":"tm2317724-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465923067689/tm2317724-1_4seq1.xml","form_type":"4"}},{"id":1870383,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-02T23:48:09.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents settlement by the Issuer of performance stock units (\"PSUs\") granted to the Reporting Person under the Company's 2016 Equity Incentive Plan on May 31, 2022, which vested based on the Issuer's achievement of corporate performance objectives."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the \"Lock-up Date\") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date."}],"balance_after":35186,"source":{"system":"sec-edgar","filing":"0001104659-23-067689","document":"tm2317724-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465923067689/tm2317724-1_4seq1.xml","form_type":"4"}},{"id":1917333,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-04-19T20:28:50.000Z","date":"2023-04-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":1189,"price":23.21,"value":27596.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 3,437 vested restricted stock units on April 18, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the \"Lock-up Date\") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date."}],"balance_after":23186,"source":{"system":"sec-edgar","filing":"0001104659-23-047208","document":"tm2312473-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465923047208/tm2312473-2_4seq1.xml","form_type":"4"}},{"id":2052766,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-19T00:53:31.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":63750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":63750,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":63750},"source":{"system":"sec-edgar","filing":"0001104659-23-004725","document":"tm233829-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465923004725/tm233829-3_4seq1.xml","form_type":"4"}},{"id":2052765,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-19T00:53:31.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":10625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on January 15, 2024, 2025 and 2026."}],"balance_after":24375,"source":{"system":"sec-edgar","filing":"0001104659-23-004725","document":"tm233829-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465923004725/tm233829-3_4seq1.xml","form_type":"4"}},{"id":2294936,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-04-19T23:48:56.000Z","date":"2022-04-18","kind":"grant","acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option represents a right to purchase a total of 82,500 shares of the Issuer's common stock, one quarter of which will vest on April 18, 2023, with the remaining three quarters vesting in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":82500,"derivative":{"exercise_price":19.19,"expiration_date":"2032-04-18","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001104659-22-047468","document":"tm2212815-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465922047468/tm2212815-3_4seq1.xml","form_type":"4"}},{"id":2294935,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":51805,"kind":"person","name":"Ali Asif","position":1,"cik":"0001921163","reported_name":"Ali Asif","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-19T23:48:56.000Z","date":"2022-04-18","kind":"grant","acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in shares of the Issuer's common stock that will vest in four annual installments on April 18, 2023, 2024, 2025 and 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":13750,"source":{"system":"sec-edgar","filing":"0001104659-22-047468","document":"tm2212815-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1921163/000110465922047468/tm2212815-3_4seq1.xml","form_type":"4"}}]}